A Phase 3 interventional study of SPD489 (Lisdexamfetamine dimesylate) + Antidepressant in Major Depressive Disorder, sponsored by Shire. Terminated at 212 sites in 14 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one has the largest enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2012, is one of 16 in phase 3, and was the 15th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 17 · Phase 4 3
First in 2008; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,570 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 580 across the 24 interventional studies, 73,904 across the 2 observational. Of the 25 that completed or were terminated, 24 (96%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Depressive Disorder, Major by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous double-blind MDD augmentation study using SPD489.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug page: Lisdexamfetamine
SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
Also known as: Vyvanse, LDX
Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviour during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: Week 5 up to Week 52/Early Termination(ET)
Change From Baseline in Systolic Blood Pressure at Week 52
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
Time frame: Baseline, Week 52/ET
Change From Baseline in Diastolic Blood Pressure at Week 52
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
Time frame: Baseline, Week 52/ET
Change From Baseline in Pulse Rate at Week 52
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
Time frame: Baseline, Week 52/ET
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 52/ET
Designed to evaluate the extent to which illness symptoms impact a participant's life in 3 areas: work, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
Time frame: Baseline, Week 52/ET
Number of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I)
Participants who did not have Clinical Global Impressions - Severity of Illness (CGI-S) assessed at Week 8 in the antecedent study should not have had CGI-I assessed in this study and were excluded from the summary of CGI-I. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Week 52/ET
Short Form-12 Health Survey Version 2 (SF-12V2)
SF-12V2 is a multi-purpose, 7-item survey that measures 8 domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. It is expressed by two summary measures (Aggregate Physical and Aggregate Mental) for which values can range from 0 to 100. A higher score is indicative of a better health state.
Time frame: Week 52/ET
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Mobility
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
Time frame: Week 52/ET
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Self-Care
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
Time frame: Week 52/ET
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Usual Activities
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
Time frame: Week 52/ET
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Pain/Discomfort
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
Time frame: Week 52/ET
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Anxiety/Depression
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
Time frame: Week 52/ET
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale
EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. EQ-5D-5L Visual Analog Scale score is numbered from 0 to 100, where a score of 100 is the best health a participant can imagine
Time frame: Week 52/ET
Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression. The QIDS-SR was only assessed in the SPD489-322 antecedent study. The QIDS-SR total score is calculated as the sum of the highest score on any 1 of Items 1-4, Item 5, the highest score on any 1 of Items 6-9, Items 10-14, the highest score on either Item 15 or 16.
Time frame: Week 52/ET
Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)
The Q-LES-Q-SF is a 16-item self-report questionnaire which evaluates general participant satisfaction with health, mood, relationships, functioning in daily life, and their treatment. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total raw score (summary scale score) was calculated by summing item scores 1 to 14 (total raw score range: 14 to 70). Item 15 (satisfaction with medication, raw score range: 1 to 5) and Item 16 (overall satisfaction and contentment; raw score range: 1 to 5) were stand-alone items. For reporting, summary scale, Item 15 and Item 16 raw scores were transformed into percentage maximum possible score which ranged from 0 to 100, where higher scores are indicative of greater enjoyment or satisfaction.
Time frame: Week 52/ET
Change From Baseline in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score at Week 52/ET
CSFQ-14 is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
Time frame: Baseline, Week 52/ET
Amphetamine Cessation Symptom Assessment (ACSA) Total Score
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Time frame: Week 53
Patient Resource Utilization Questionnaire - Major Depressive Disorder (PRUQ-MDD)
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered the following questions: 1. Were you hospitalized in the past month, 2. Do you work for pay, 3. If you missed time at work last week, please note all the reasons why, 4. Would you say that the past week was typical, like the rest of the 3 weeks this month, in terms of your working hours, 5. Do you do volunteer work (VW), and 6. If you do not receive money for your work and do not participate in volunteer work, the reason is. Number of participants with response is reported.
Time frame: Week 52/ET
PRUQ-MDD - Number of Days of Resource Utilization
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Number of nights in medical/surgical ward, number of nights in ICU, and number of days a participant received home care in the past month are reported.
Time frame: Week 52/ET
PRUQ-MDD - Number of Events (Visit to Health Care Provider/Visit to Hospital Facilities/Number of Times a Test Was Performed)
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many times did you visit the following healthcare providers in the past month: Family doctor/primary care, Non-physician healthcare practitioner (NPHP), Psychiatrist/Psychologist/Counselor (PPC); 2. How many times did you take one of the tests, mentioned below, during the past month: Blood test, CT Scan, X Ray, Renal function, Thyroid function; and 3. How many times did you visit the hospital emergency room (ER), urgent care facility (UCF) or an after-hours clinic (AHC) in the past month. Number of events (visit to health care provider, visit to hospital facilities, and number of times a test was performed) are reported.
Time frame: Week 52/ET
PRUQ-MDD - Number of Hours
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many hours do you usually work or would you usually be expected to work (hrs/week); 2. How many hours did you actually work last week; 3. On average, how many hours do you volunteer per week. Number of hours are reported.
Time frame: Week 52/ET
PRUQ-MDD - Effect of Depressive Symptoms
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions on a 0 to 10 point scale - 1. During past week, how much did depressive symptoms affect work productivity; 2. During past week, how much did depressive symptoms affect regular non-work daily activities. Higher scores indicates more effect of depressive symptoms on work productivity and non-work daily activities.
Time frame: Week 52/ET
Study enrolled eligible adults with major depressive disorder (MDD) who had completed treatment in a short-term antecedent SPD489 (lisdexamfetamine dimesylate) MDD study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
| Milestone | SPD489 + Antidepressant |
|---|---|
| Started | 1570 |
| Completed | 300 |
| Not completed | 1270 |
| Withdrew: Adverse event | 111 |
| Withdrew: Protocol violation | 49 |
| Withdrew: Withdrawal by subject | 108 |
| Withdrew: Lost to follow-up | 89 |
| Withdrew: Lack of efficacy | 24 |
| Withdrew: Met blood pressure or pulse withdrawal | 63 |
| Withdrew: Other | 826 |
C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviour during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
| participants | SPD489 + Antidepressant |
|---|---|
| Positive Suicidal Ideation | 68 |
| Suicidal Attempt | 4 |
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
| millimeter of mercury(mmHg) | SPD489 + Antidepressant |
|---|---|
| Baseline (n = 1559) | 117.6 ± 11.13 |
| Change at Week 52/ET (n = 1558) | 2.4 ± 10.37 |
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
| mmHg | SPD489 + Antidepressant |
|---|---|
| Baseline (n = 1559) | 75.4 ± 8.15 |
| Change at Week 52/ET (n = 1558) | 1.2 ± 7.94 |
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
| beats per minute(bpm) | SPD489 + Antidepressant |
|---|---|
| Baseline (n = 1559) | 72.7 ± 9.90 |
| Change at Week 52/ET (n = 1558) | 5.2 ± 10.58 |
Designed to evaluate the extent to which illness symptoms impact a participant's life in 3 areas: work, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
| units on a scale | SPD489 + Antidepressant |
|---|---|
| Baseline (n=1548) | 12.7 ± 7.06 |
| Change at Week 52/ET (n = 1530) | -4.3 ± 7.77 |
Participants who did not have Clinical Global Impressions - Severity of Illness (CGI-S) assessed at Week 8 in the antecedent study should not have had CGI-I assessed in this study and were excluded from the summary of CGI-I. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.
| participants | SPD489 + Antidepressant |
|---|---|
| Number of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I) | 1021 |
SF-12V2 is a multi-purpose, 7-item survey that measures 8 domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. It is expressed by two summary measures (Aggregate Physical and Aggregate Mental) for which values can range from 0 to 100. A higher score is indicative of a better health state.
| units on a scale | SPD489 + Antidepressant |
|---|---|
| Aggregate Physical | 49.1 ± 9.67 |
| Aggregate Mental | 42.7 ± 11.55 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
| participants | SPD489 + Antidepressant |
|---|---|
| No problems in walking about | 1193 |
| Slight problems in walking about | 237 |
| Moderate problems in walking about | 82 |
| Severe problems in walking about | 24 |
| Unable to walk about | 1 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
| participants | SPD489 + Antidepressant |
|---|---|
| No problems washing or dressing myself | 1304 |
| Slight problems washing or dressing myself | 174 |
| Moderate problems washing or dressing myself | 49 |
| Severe problems washing or dressing myself | 9 |
| Unable to wash or dress myself | 1 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
| participants | SPD489 + Antidepressant |
|---|---|
| No problems doing my usual activities | 800 |
| Slight problems doing my usual activities | 475 |
| Moderate problems doing my usual activities | 197 |
| Severe problems doing my usual activities | 55 |
| Unable to do my usual activities | 10 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
| participants | SPD489 + Antidepressant |
|---|---|
| No pain or discomfort | 715 |
| Slight pain or discomfort | 536 |
| Moderate pain or discomfort | 208 |
| Severe pain or discomfort | 68 |
| Extreme pain or discomfort | 10 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses
| participants | SPD489 + Antidepressant |
|---|---|
| Not anxious or depressed | 461 |
| Slightly anxious or depressed | 687 |
| Moderately anxious or depressed | 289 |
| Severely anxious or depressed | 73 |
| Extremely anxious or depressed | 27 |
EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. EQ-5D-5L Visual Analog Scale score is numbered from 0 to 100, where a score of 100 is the best health a participant can imagine
| units on a scale | SPD489 + Antidepressant |
|---|---|
| EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale | 75.7 ± 18.35 |
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression. The QIDS-SR was only assessed in the SPD489-322 antecedent study. The QIDS-SR total score is calculated as the sum of the highest score on any 1 of Items 1-4, Item 5, the highest score on any 1 of Items 6-9, Items 10-14, the highest score on either Item 15 or 16.
| units on a scale | SPD489 + Antidepressant |
|---|---|
| Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR) | 6.9 ± 4.48 |
The Q-LES-Q-SF is a 16-item self-report questionnaire which evaluates general participant satisfaction with health, mood, relationships, functioning in daily life, and their treatment. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total raw score (summary scale score) was calculated by summing item scores 1 to 14 (total raw score range: 14 to 70). Item 15 (satisfaction with medication, raw score range: 1 to 5) and Item 16 (overall satisfaction and contentment; raw score range: 1 to 5) were stand-alone items. For reporting, summary scale, Item 15 and Item 16 raw scores were transformed into percentage maximum possible score which ranged from 0 to 100, where higher scores are indicative of greater enjoyment or satisfaction.
| units on a scale | SPD489 + Antidepressant |
|---|---|
| Summary Scale (n = 506) | 61.5 ± 17.22 |
| Satisfaction with Medication (n = 478) | 68.6 ± 19.66 |
| Overall Satisfaction and Contentment (n = 506) | 63.2 ± 21.58 |
CSFQ-14 is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).
| units on a scale | SPD489 + Antidepressant |
|---|---|
| Male: Baseline (n=167) | 46.6 ± 9.17 |
| Male: Change at Week 52/ET (n=164) | 1.7 ± 7.16 |
| Female: Baseline (n=341) | 37.2 ± 9.65 |
| Female: Change at Week 52/ET (n=330) | 2.8 ± 8.33 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
| units on a scale | SPD489 + Antidepressant |
|---|---|
| Amphetamine Cessation Symptom Assessment (ACSA) Total Score | 14.3 ± 10.59 |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered the following questions: 1. Were you hospitalized in the past month, 2. Do you work for pay, 3. If you missed time at work last week, please note all the reasons why, 4. Would you say that the past week was typical, like the rest of the 3 weeks this month, in terms of your working hours, 5. Do you do volunteer work (VW), and 6. If you do not receive money for your work and do not participate in volunteer work, the reason is. Number of participants with response is reported.
| participants | SPD489 + Antidepressant |
|---|---|
| Hospitalized in Past Month | 4 |
| Work for Pay | 337 |
| Reason Missing Work Time: Had a Day Off | 24 |
| Reason Missing Work Time: Physically Ill | 10 |
| Reason Missing Work Time: Upset/Depressed/Nervous | 15 |
| Reason Missing Work Time: Other | 36 |
| Past Week Was Typical: Yes | 249 |
| Past Week Was Typical: No, Worked More Hours | 43 |
| Past Week Was Typical: No, Worked Less Hours | 45 |
| Volunteer Work | 86 |
| Reason no Money/VW: Physically Ill | 6 |
| Reason no Money/VW: Upset/Depressed/Nervous | 30 |
| Reason no Money/VW: Cannot Find Work | 39 |
| Reason no Money/VW: Other | 48 |
| Reason no Money/VW: Not Applicable | 348 |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Number of nights in medical/surgical ward, number of nights in ICU, and number of days a participant received home care in the past month are reported.
| days | SPD489 + Antidepressant |
|---|---|
| Number of nights in medical/surgical ward (n=4) | 1.3 ± 0.50 |
| Number of nights in ICU (n=4) | 0.0 ± 0.00 |
| Number of days received home care in past month | 0.0 ± 0.00 |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many times did you visit the following healthcare providers in the past month: Family doctor/primary care, Non-physician healthcare practitioner (NPHP), Psychiatrist/Psychologist/Counselor (PPC); 2. How many times did you take one of the tests, mentioned below, during the past month: Blood test, CT Scan, X Ray, Renal function, Thyroid function; and 3. How many times did you visit the hospital emergency room (ER), urgent care facility (UCF) or an after-hours clinic (AHC) in the past month. Number of events (visit to health care provider, visit to hospital facilities, and number of times a test was performed) are reported.
| events | SPD489 + Antidepressant |
|---|---|
| Visit to Family doctor/primary care (n=481) | 0.2 ± 0.58 |
| Visit to NPHP(n=480) | 0.1 ± 0.43 |
| Visit to PPC(n=481) | 0.1 ± 0.86 |
| Test performed: Blood Test (n=480) | 0.2 ± 2.30 |
| Test performed: CT Scan (n=480) | 0.0 ± 0.08 |
| Test performed: X Ray (n=480) | 0.0 ± 0.20 |
| Test performed: Renal function (n=480) | 0.0 ± 0.00 |
| Test performed: Thyroid function (n=480) | 0.0 ± 0.09 |
| Test performed: Other test (n=479) | 0.1 ± 0.49 |
| Visit to Hospital ER, UCF or AHC (n=482) | 0.0 ± 0.23 |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many hours do you usually work or would you usually be expected to work (hrs/week); 2. How many hours did you actually work last week; 3. On average, how many hours do you volunteer per week. Number of hours are reported.
| hours | SPD489 + Antidepressant |
|---|---|
| Work or usually expect to work (n=337) | 34.0 ± 11.85 |
| Actual work (n=337) | 31.2 ± 15.13 |
| Average volunteer per week (n=86) | 8.6 ± 8.94 |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions on a 0 to 10 point scale - 1. During past week, how much did depressive symptoms affect work productivity; 2. During past week, how much did depressive symptoms affect regular non-work daily activities. Higher scores indicates more effect of depressive symptoms on work productivity and non-work daily activities.
| units on scale | SPD489 + Antidepressant |
|---|---|
| Affected work productivity (n= 335) | 2.1 ± 2.37 |
| Affected regular non work daily activities (n=482) | 2.5 ± 2.43 |
Collected over Up to Week 53. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPD489 + Antidepressant | — | 33/1,559 (2.1%) | 921/1,559 (59.1%) |
| Event | SPD489 + Antidepressant |
|---|---|
| Suicidal ideationPsychiatric disorders | 3/1559 |
| Suicide attemptPsychiatric disorders | 3/1559 |
| Non-Cardiac chest painGeneral disorders | 2/1559 |
| DepressionPsychiatric disorders | 2/1559 |
| Deep vein thrombosisVascular disorders | 2/1559 |
| Angina pectorisCardiac disorders | 1/1559 |
| Abdominal painGastrointestinal disorders | 1/1559 |
| Intestinal strangulationGastrointestinal disorders | 1/1559 |
| Small intestinal obstructionGastrointestinal disorders | 1/1559 |
| Chest painGeneral disorders | 1/1559 |
| Event | SPD489 + Antidepressant |
|---|---|
| HeadacheNervous system disorders | 241/1559 |
| Dry mouthGastrointestinal disorders | 212/1559 |
| InsomniaPsychiatric disorders | 204/1559 |
| Decreased appetiteMetabolism and nutrition disorders | 189/1559 |
| NasopharyngitisInfections and infestations | 137/1559 |
| NauseaGastrointestinal disorders | 116/1559 |
| Upper respiratory tract infectionInfections and infestations | 100/1559 |
| DizzinessNervous system disorders | 91/1559 |
| BruxismPsychiatric disorders | 89/1559 |
| AnxietyPsychiatric disorders | 83/1559 |
Safety analysis set included all participants who took at least 1 dose of investigational product and had at least 1 post-Visit 0 (Week 0) safety assessment in this study.
| Age, Continuous(years) | SPD489 + Antidepressant |
|---|---|
| Mean | 41.9 ± 11.89 |
| Age, Customized(Participants) | SPD489 + Antidepressant |
|---|---|
| 18-55 Years | 1333 |
| 56-65 Years | 226 |
| Sex: Female, Male(Participants) | SPD489 + Antidepressant |
|---|---|
| Female | 1056 |
| Male | 503 |
| Region of Enrollment(Participants) | SPD489 + Antidepressant |
|---|---|
| United States | 1190 |
| Estonia | 24 |
| Hungary | 4 |
| Czech Republic | 83 |
| Mexico | 27 |
| Canada | 36 |
| Finland | 8 |
| Spain | 6 |
| Poland | 20 |
| Romania | 8 |
| South Africa | 5 |
| Chile | 33 |
| Germany | 69 |
| Argentina | 27 |
| Australia | 13 |
| United Kingdom | 1 |
| Croatia | 5 |
Showing the first 100 of 212 sites across 14 countries. Choose a country and city above to see the rest.
Ran from Feb 2012 to primary completion in Mar 2014, 25 months.
Results were first posted in Feb 2015, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine